<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00914940</url>
  </required_header>
  <id_info>
    <org_study_id>2222.00</org_study_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>P01CA018029</secondary_id>
    <secondary_id>IR-6907</secondary_id>
    <secondary_id>CDR0000644201</secondary_id>
    <secondary_id>0903004832</secondary_id>
    <nct_id>NCT00914940</nct_id>
  </id_info>
  <brief_title>Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD</brief_title>
  <official_title>A Multi-center Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Allogeneic hematopoietic stem cell transplant (HSCT) is a treatment that can cure
      acute leukemia and myelodysplasia. After giving the patient chemotherapy and total body
      irradiation to stop the growth of cancer and remove the patient's diseased bone marrow,
      healthy stem cells from a donor are infused into the patient to replace the patient's bone
      marrow and make red and white blood cells and platelets. Unfortunately HSCT is often
      complicated by 'graft versus host disease' (GVHD) in which the transplanted cells from a
      donor can make an immune response against the body's normal cells and cause tissue damage and
      severe symptoms. Removing a subset of the donor T cells, called 'naive T cells', before
      transplant may reduce the frequency and intensity of GVHD.

      PURPOSE: This phase II trial will determine whether the removal of the naive T cells from
      donor cells can decrease the rate and severity of graft-vs-host disease while preserving
      specific immunity against infections in patients with acute leukemia or advanced
      myelodysplastic syndromes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Estimate the probability of grades II-IV acute graft-vs-host disease (GVHD) in patients
           with acute leukemia or advanced myelodysplastic syndromes treated with CD45RA+
           T-cell-depleted allogeneic peripheral blood stem cell transplantation and compare this
           to relevant historical experience.

        -  Estimate the probability of graft failure in these patients.

      Secondary

        -  Evaluate immune reconstitution and pathogen-specific T-cell reconstitution in these
           patients.

        -  Estimate the probability of transplant-related mortality by day 100 in these patients.

        -  Estimate the probability of relapse in these patients.

        -  Estimate the probability and severity of chronic GVHD in these patients.

      OUTLINE: This is a multicenter study.

        -  Myeloablative conditioning regimen: Patients undergo total body irradiation twice daily
           for 4 days (Days -10 to -7) Patients also receive thiotepa IV over 4 hours for 2 days
           (Days -6 and -5) and fludarabine phosphate IV over 30 minutes for 5 days (Days -6 to
           -2.)

        -  Transplantation: Patients receive a CD34+ enriched allogeneic peripheral blood stem cell
           (PBSC) product followed by a CD45RA+ T-cell-depleted allogeneic PBSC product on day 0.

        -  Graft-vs-host disease (GVHD) prophylaxis: Patients will receive Tacrolimus as per cohort
           1. If the rate of grade II-IV acute GVHD in the first 35 patients is significantly
           reduced (compared to historical controls), subsequent patients are enrolled in cohort 2.

             -  Cohort 1: Patients receive tacrolimus IV continuously or orally twice daily
                beginning on day -1 and continuing until day 50, followed by a standard taper in
                the absence of grade II-IV acute GVHD.

             -  Cohort 2: Patients receive tacrolimus IV continuously or orally twice daily
                beginning on day -1 and continuing until day 30, followed by a rapid taper in the
                absence of grade II-IV acute GVHD.

      Patients are followed actively for at least 1 year post transplant.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of grade II-IV acute graft-vs-host disease (GVHD)</measure>
    <time_frame>Start of study to day 100</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of engraftment</measure>
    <time_frame>Up to 5 years post transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of recovery of T-cell immunity to pathogens</measure>
    <time_frame>Start of study to day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of transplant-related mortality at day 100</measure>
    <time_frame>Start of study to day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of relapse</measure>
    <time_frame>Up to 5 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and severity of chronic GVHD</measure>
    <time_frame>Up to 1 year post transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING: Patients undergo total-body irradiation twice daily on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine IV over 30 minutes on days -6 to -2. TRANSPLANTATION: Patients undergo infusion of CD34+ enriched allogeneic peripheral blood stem cells (PBSC) followed by CD45RA+ T-cell-depleted allogeneic PBSC on day 0.
GRAFT-VS-HOST DISEASE PROPHYLAXIS: Cohort A: Patients receive tacrolimus IV continuously or orally twice daily beginning on day -1 and continuing until day 50 followed by standard taper in the absence of grade II-IV acute GVHD. Cohort B: Patients receive tacrolimus IV continuously or orally twice daily beginning on day -1 and continuing until day 30 followed by rapid taper in the absence of grade II-IV acute GVHD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Fludarabine will be administered in a dose of 25 mg/m2/day IV over approximately 30 minutes for 5 consecutive days (day -6 to -2). The total dose of fludarabine will be 125 mg/m2.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus will be administered beginning on day -1 at a dose of 0.03 mg/kg/day by continuous IV infusion.
For the first cohort of 35 patients, if there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus should then be tapered at the rate of approximately 5% of the day 50 dose each week for liquid, and 20% of the day 50 dose per month for capsules.
In the second cohort of 25 patients if there is no evidence of grade II GVHD on or prior to day 30, tacrolimus should then be tapered at the rate of approximately 8% of the day 30 dose each week for liquid, and 33% of the day 30 dose per month for capsules.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Advagraf</other_name>
    <other_name>FK 506</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Thiotepa will be administered in a dose of 5 mg/kg/day (adjusted body weight) IV over approximately 4 hours for 2 consecutive days (day -6 and day -5).</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>Tespamine</other_name>
    <other_name>TSPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation (TBI)</intervention_name>
    <description>TBI will be given as 165 cGy fractions twice per day x 4 days - total dose 1320cGy (days -10 to -7).</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic Affinity Cell Sorting</intervention_name>
    <description>Device</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Patient will undergo a PBSC transplantation</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Transplantation</other_name>
    <other_name>Peripheral Blood Stem Cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Patients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T Cell-Depleted Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Patients who are eligible will receive a T Cell-Depleted Hematopoietic Stem Cell Transplantation</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following:

               -  Acute lymphocytic leukemia (ALL) or acute myeloid leukemia (AML) in first or
                  subsequent remission

               -  ALL or AML in relapse or primary refractory ALL or AML with a circulating blast
                  count â‰¤ 10,000/mm^3

               -  Refractory anemia with excess blasts (RAEB) (RAEB-1 or RAEB-2) if the patient has
                  received induction chemotherapy within the past 60 days

          -  Appropriate candidate for allogeneic hematopoietic stem cell transplantation (HSCT)

          -  No CNS involvement refractory to intrathecal chemotherapy and/or standard
             cranial-spinal radiotherapy

        PATIENT CHARACTERISTICS:

          -  Age 14-55

          -  Creatinine &lt; 1.5 mg/dL

          -  Cardiac ejection fraction &gt; 45%

          -  DLCO corrected &gt; 60% of predicted

          -  Total bilirubin &lt; 2 times upper limit of normal (ULN) (unless attributed to Gilbert
             syndrome)

          -  AST and ALT &lt; 2 times ULN

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 12 months after
             transplantation

          -  HIV negative

          -  No co-existing disease (other than leukemia or RAEB) that would limit life expectancy
             to &lt; 3 months

          -  No uncontrolled infection that, in the opinion of the consulting infectious disease
             physician, would contraindicate myeloablative HSCT

          -  No other medical condition that would contraindicate HSCT

          -  No known hypersensitivity to tacrolimus

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior HSCT

          -  No concurrent participation in other experimental studies for the prevention of
             graft-vs-host disease

        DONOR CHARACTERISTICS:

          -  Genotypic or phenotypic HLA-identical related donor

          -  Able to donate peripheral blood stem cells

          -  Age &gt; 14 years

          -  Applicable to male patients only: No female donors who have previously given birth to
             a male child or have had a pregnancy beyond the first trimester miscarriage or
             termination of pregnancy or nursing

          -  No donors who have received blood transfusions

          -  No CD45 Mutation with aberrant CD45RA isoform expression
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Bleakley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Warren Shlomchik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University School of Medicine/Yale New Haven Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine/Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2009</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>graft versus host disease</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

